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based	 on	 spread	 to	 the	 retroperitoneal	 lymph	 nodes	 alone	without	 intraperitoneal	
	dissemination.	 This	 category	 is	 now	 subdivided	 into	 IIIA1(i)	 (metastasis	 ≤10	mm	 in	
greatest	dimension),	and	IIIA1(ii)	(metastasis	>10	mm	in	greatest	dimension).	Stage	IIIA2	
is	 now	 “microscopic	 extrapelvic	 peritoneal	 involvement	 with	 or	 without	 positive	
	retroperitoneal	lymph	node”	metastasis.	This	review	summarizes	the	genetics,	surgical	
management,	 chemotherapy,	 and	 targeted	 therapies	 for	 epithelial	 cancers,	 and	 the	
treatment	of	ovarian	germ	cell	and	stromal	malignancies.
K E Y W O R D S
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1  | INTRODUCTION






or	 peritoneum)	 is	 designated,	 where	 possible.	When	 it	 is	 not	 pos-
sible	 to	 clearly	delineate	 the	primary	 site,	 these	 should	be	 listed	 as	
“undesignated”.1,2
It	has	been	presumed	that	fallopian	tube	malignancies	were	rare.2 








no	 longer	 be	 used,	 unless	 that	 is	 clearly	 the	 origination	 site.	 It	 has	
been	suggested	 that	extrauterine	 tumors	of	 serous	histology	arising	
in	 the	 ovary,	 fallopian	 tube,	 or	 peritoneum	might	 be	 described	 col-
lectively	as	 “Müllerian	carcinomas”1,2	or	 “pelvic	serous	carcinomas”.9 
The	latter	tumor	designation	is	controversial	because	some	peritoneal	





















1.1.2 | Lymphatic and lymph node drainage
The	 lymphatic	drainage	of	 the	ovaries	and	fallopian	tubes	 is	via	 the	
utero-	ovarian,	infundibulopelvic,	and	round	ligament	pathways	and	an	
external	iliac	accessory	route	into	the	following	regional	lymph	nodes:	





































serosa	 can	 therefore	 be	 defined.	 These	 features,	 together	with	 the	
laterality	and	the	presence	or	absence	of	ascites,	should	all	be	taken	
into	consideration.1,3,6,7
In	 the	 second	 scenario,	 a	widespread	 serous	 carcinoma	 is	 asso-
ciated	 with	 a	 tubal	 intraepithelial	 carcinoma.	 A	 visible	 mass	 in	 the	






In	 the	 third	 scenario—	 risk-	reducing	 salpingo-	oophorectomy—












In	 addition	 to	 these	 changes,	 several	 other	modifications	 of	 the	
former	staging	system	have	been	made	to	better	prospectively	capture	




a	 revision	 of	 the	 Stage	IIIC	 based	 on	 spread	 to	 the	 retroperitoneal	
lymph	nodes	alone	without	intraperitoneal	dissemination,	because	an	
analysis	of	 these	patients	 indicates	 that	 their	 survival	 is	 significantly	
better	than	those	who	have	intraperitoneal	dissemination.17	This	cat-
egory	 is	now	subdivided	 into	 IIIA1(i)	 (metastasis	≤10	mm	 in	greatest	
dimension),	 and	 IIIA1(ii)	 (metastasis	 >10	mm	 in	 greatest	 dimension).	
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1.2.2.1 | Regional lymph nodes (N)




1.	 MX:	 Distant	 metastasis	 cannot	 be	 assessed.
2.	 M0:	No	distant	metastasis.
3.	 M1:	Distant	metastasis	(excluding	peritoneal	metastasis).
T A B L E  1  FIGO	staging	classification	for	cancer	of	the	ovary,	fallopian	tube,	and	peritoneum.





















Stage III: Tumor involves 1 or both ovaries or fallopian tubes, or peritoneal cancer, with cytologically or histologically  


































epithelial	 structure,	 but	 they	 are	 too	 poorly	 differentiated	 to	 be	
placed	in	any	other	group).


















Serous	carcinomas	are	 the	most	common	 in	both	 the	ovary	and	
tube.	More	than	90%	of	fallopian	tube	carcinomas	are	serous	or	high-	
grade	 endometrioid	 adenocarcinoma.	 Other	 cell	 types	 have	 been	
reported,	 but	 are	 rare.1,2,20	 Serous	 carcinomas	 are	 graded	 in	 a	 two-	
grade	 system	befitting	 their	 biology.	High-	grade	 serous	 carcinomas,	
including	both	 classic	 appearing	 and	 those	with	 SET	 features	 (solid,	









neoplasms	 to	 the	 ovary,	 such	 as	 tumors	 arising	 in	 the	 breast,	 lower	
reproductive	tract	sites	(cervix	or	uterine	carcinomas)	and	gastrointes-






T A B L E  2  Cancer	of	the	ovary,	fallopian	tube	and	peritoneum:	
FIGO	staging	(2014)	compared	with	TNM	classification.a
FIGO (designate primary: 




IA T1a N0 M0
IB T1b N0 M0
IC T1c N0 M0
IIA T2a N0 M0
IIB T2b N0 M0
IIIA T3a N0 M0
T3a N1 M0
IIIB T3b N0 M0
T3b N1 M0
IIIC T3c N0–1 M0
T3c N1 M0























fication	 for	 cancer	 of	 the	 ovary,	 fallopian	 tube,	 and	 peritoneum.	 Int	 J	
Gynecol	Obstet.	2014;124:1–5.























As	 noted	 above,	 it	 has	 been	 previously	 presumed	 that	 fallopian	











in	 either	 the	 BRCA1 or BRCA2	 genes.	 At	 least	 15%	 of	 women	
with	 high-grade	 nonmucinous	 ovarian	 cancers	 have	 germline	
mutations	 in	 BRCA1/2	 and,	 importantly,	 almost	 40%	 of	 these	
women	 do	 not	 have	 a	 family	 history	 of	 breast/ovarian	 cancer.	
All	women	with	high-grade	nonmucinous	invasive	ovarian	cancers	
should	 be	 offered	 genetic	 testing	 even	 if	 they	 do	 not	 have	 a	
family	 history	 of	 breast/ovarian	 cancer.
2.	 Inherited	 deleterious	 mutations	 in	 BRCA1	 and	 BRCA2	 are	 the	
major	genetic	risk	factors.	Women	who	carry	germline	mutations	
in BRCA1	and	BRCA2	have	a	substantially	increased	risk	of	ovarian,	












pathway	genes	(including	BRIP1, BARD1, PALB2, RAD50, RAD51C,	
and	 RAD51D,	 among	 others).	 About	 80%	 of	 mutations	 were	 in	
BRCA1 or BRCA2.	About	3%	of	patients	carried	mutations	 in	 the	
Fanconi	Anemia	pathway	genes,	while	only	0.4%	had	mutations	in	
mismatch	 repair	genes.33	 In	an	earlier	 similar	 study	 that	 included	















genetic	 testing.	BRCA	mutations	may	also	occur	 in	women	without	 a	
family	history	of	breast/ovarian	 cancer,	 and	genetic	 testing	 should	be	
considered	 in	 patients	 from	ethnic	 groups	where	 there	 is	 a	 high	 inci-
dence	 of	 founder	 mutations	 (e.g.	 Ashkenazi	 Jewish	 ancestry),	 and	 in	
women	with	high-	grade	serous	cancers	under	the	age	of	70	years.26–30 















based	on	 trials	 carried	out	 in	women	 in	 the	 general	 population	 and	
those	 in	 the	 high-	risk	 population.	 The	US	 Preventive	 Services	 Task	
Force	 recommends	 against	 screening	 asymptomatic	 women	 for	
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ovarian	 cancer	with	 pelvic	 examination,	 pelvic	 ultrasound,	 or	 serum	
tumor	 marker	 measurements.38	 The	 low	 prevalence	 of	 disease	 and	
lack	of	high-	quality	screening	methods	make	it	more	likely	to	obtain	
false-	positive	 results	 leading	 to	unnecessary	 interventions.	A	 recent	
study	of	multimodal	screening	using	CA125	based	on	a	risk	of	ovarian	
cancer	algorithm	(ROCA)	every	4	months	and	transvaginal	ultrasound	
annually	 or	 earlier	where	 indicated	by	 the	ROCA	 in	women	 at	 high	
risk	 of	 ovarian	 cancer	 reported	 that	 screening	 was	 associated	 with	
a	 low	 rate	of	high-	volume	disease	at	primary	 surgery	and	very	high	




















various	 histologic	 subtypes;	 for	 example,	 grade	1	 serous,	 clear	 cell,	
mucinous,	 and	 endometrioid	 cancers	 are	 commonly	 early	 stage	 at	
presentation,	whereas	high-	grade	serous	cancers	are	most	often	Stage	
III	because	of	early	dissemination	by	a	more	aggressive	cancer.	Tumor	
markers	 such	 as	 human	 gonadotropin	 (hCG)	 and	 alpha-	fetoprotein	
(AFP)	are	mandatory	to	exclude	germ	cell	tumors	in	younger	patients	
with	a	pelvic	mass	or	suspicious	enlargement	of	an	ovary.
Approximately	 two-	thirds	of	 all	 epithelial	 “ovarian”	 cancers	 are	
Stage	III	or	Stage	IV	at	diagnosis.	Presenting	symptoms	include	vague	
abdominal	 pain	 or	 discomfort,	 menstrual	 irregularities,	 dyspepsia,	
and	other	mild	digestive	disturbances,	which	may	have	been	pres-
ent	for	only	a	few	weeks.13,14,46	As	the	disease	progresses,	abdom-












a	pleural	 effusion	and	a	CT	 scan	of	 the	abdomen	and	pelvis	 should	







































4.	 Selective	 lymphadenectomy	 of	 the	 pelvic	 and	 para-aortic	 lymph	
nodes,	at	least	ipsilateral	if	the	malignancy	is	unilateral.
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5.	 Biopsy	or	resection	of	any	suspicious	lesions,	masses,	or	adhesions.
6.	 Random	peritoneal	biopsies	of	normal	surfaces,	including	from	the	
undersurface	of	 the	 right	hemidiaphragm,	bladder	 reflection,	cul-
de-sac,	right	and	left	paracolic	recesses,	and	both	pelvic	sidewalls.

















servative	 surgery,	with	 preservation	 of	 the	 uterus	 and	 contralateral	
ovary,	should	be	considered	after	informed	consent.43
Clinical	 judgment	 is	 important	 in	 the	 approach	 to	 a	 pelvic	
mass	 in	 the	 young,	 reproductive-	aged	 woman.	 If	 the	 suspicion	
is	 strong	 for	 malignancy,	 open	 laparotomy	 is	 generally	 indicated.	
Laparoscopy	may	be	more	appropriate	if	the	suspicion	is	more	for	
benign	disease,	where	tumor	markers	(including	hCG	and	AFP)	are	
normal.	A	 biopsy	 of	 any	 suspicious	 lesion	 can	 be	 performed	 and	














advanced	stage	ovarian	cancer	 is	 the	volume	of	 residual	disease	after	





organs.	 Systematic	 pelvic	 and	 para-	aortic	 lymphadenectomy	 of	 non-	
enlarged	nodes	does	not	improve	overall	survival,	when	compared	with	
removal	of	bulky	nodes	only,	although	there	is	a	modest	improvement	in	




chemotherapy	 (NACT)	 may	 be	 given	 initially,	 followed	 by	 interval	























6.1 | Chemotherapy for early stage cancer
The	prognosis	of	patients	with	adequately	staged	tumors	with	Stage	
IA	and	Stage	IB	grade	1–2	epithelial	cancers	of	the	ovary	is	very	good;	
adjuvant	 chemotherapy	 does	 not	 provide	 additional	 benefits	 and	 is	




surgical	 staging.42	 All	 patients	 with	 Stage	II	 disease	 should	 receive	







of	the	fallopian	tube	and	it	is	not	recommended.1,2,44 Level of Evidence A
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6.2 | Chemotherapy for advanced stage 
ovarian cancer
Patients	who	have	had	primary	cytoreduction	should	receive	chemo-
therapy	 following	 surgery1,59	 (Table	3).	 The	 accepted	 standard	 is	 6	
cycles	of	platinum-	based	combination	chemotherapy,	with	a	platinum	
(carboplatin	or	 cisplatin)	 and	 a	 taxane	 (paclitaxel	 or	 docetaxel).60–64 




study	 randomly	 assigned	 1077	women	with	 Stages	IC–IV	 epithelial	
ovarian	cancer	 to	carboplatin	paclitaxel	or	docetaxel.60	The	efficacy	





platin/paclitaxel,	 respectively.65	 The	 median	 overall	 survival	 times	
were	 61.6	 and	 53.2	months	with	 carboplatin/PLD	 and	 carboplatin/
paclitaxel,	 respectively	 (hazard	 ratio	 [HR]	 0.89;	 95%	 CI	 0.72–1.12;	










plus	 cisplatin	with	 intravenous	paclitaxel	 plus	 intraperitoneal	 cispla-
tin	and	paclitaxel	 in	patients	with	Stage	III	ovarian	or	peritoneal	car-
cinoma,	with	no	residual	disease	greater	than	1	cm	in	diameter.68 Only 




vs	49.7	months;	P=0.03). Level of Evidence A
More	recently,	the	GOG	252	trial	reported	a	median	progression-	
free	 survival	 of	 approximately	 27–29	months	 in	 over	 1500	 patients	












(intraperitoneal	 cisplatin).	 An	 analysis	 limited	 to	 patients	 with	 opti-



























m2.70	The	Japanese	GOG	 (JGOG)	 reported	 the	findings	of	 the	 latter	
regimen	 and	 showed	 improved	progression-	free	 survival	 and	overall	









Carboplatin AUC=5–6 3 Every	3	wk 6–8 cycles
Paclitaxel 175 mg/m2
Carboplatin AUC=5–6 3 Every	3	wk 6 cycles
Paclitaxel 80 mg/m2 Every	
week
18	wk
Carboplatin AUC=5 3 Every	
week
6 cycles
Docetaxel 75 mg/m2 Every	3	wk
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by	 cisplatin	 100	mg/m2	 intraperitoneally	 on	 day	 two,	 followed	 by	
paclitaxel	60	mg/m2	intraperitoneally	on	day	eight,	every	3	weeks	for	
6	 cycles,	 as	 tolerated.68,69	Many	 centers	modify	 the	 dose	 of	 cispla-
tin	to	75	mg/m2	 rather	than	100	mg/m2	 that	was	used	 in	GOG	172	
to	reduce	toxicity,	but	this	could	be	questioned	based	on	GOG	262	
results	 discussed	 above.69	Others	 substitute	 carboplatin	 (AUC	 5–6)	




regimens.77,78	Two	 studies	 have	 reported	 a	modest,	 but	 statistically	











received	3	 cycles	 of	 neoadjuvant	 chemotherapy	 underwent	 interval	
debulking	 surgery.	These	patients	were	 then	 randomized	 to	 receive	
either	 3	 more	 cycles	 of	 paclitaxel	 plus	 carboplatin	with	 or	without	
hyperthermic	 intraperitoneal	 chemotherapy	 (HIPEC).	 The	 addi-
tion	 of	 HIPEC	 to	 interval	 cytoreductive	 surgery	 resulted	 in	 longer	
recurrence-	free	 survival	 (14.2	 vs	 10.7	months)	 and	 overall	 survival	
(45.7	 vs	 33.9	months)	 and	 did	 not	 result	 in	 higher	 rates	 of	 adverse	
effects.	These	findings	are	provocative	and	raise	important	questions.	
Unfortunately,	 the	 study	 did	 not	 have	 an	 arm	 with	 intraperitoneal	
cisplatin	 alone	without	HIPEC,	 therefore	 it	 is	 not	 possible	 to	 know	
whether	the	improved	survival	was	due	to	the	addition	of	intraperito-
neal	cisplatin	alone	or	HIPEC.
In	 patients	 who	 may	 not	 tolerate	 combination	 chemotherapy	
because	of	medical	comorbidities	or	advanced	age,	single-	agent,	intra-
venously	administered	carboplatin	(AUC	5–6)	can	be	given.
For	 patients	who	 have	 a	 significant	 hypersensitivity	 reaction	 to	
paclitaxel,	an	alternative	active	drug	can	be	substituted	(e.g.	docetaxel,	
nanoparticle	paclitaxel,	or	liposomal	doxorubicin).	Carboplatin	hyper-















ducted	to	determine	 if	 there	 is	a	benefit	of	maintenance	therapy	 in	
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of	 first-	line	 chemotherapy	 to	 determine	 response	 to	 treatment.	
Although	of	prognostic	value,	it	has	not	been	shown	to	influence	sur-
vival,	and	is	no	longer	recommended	as	part	of	the	standard	of	care.87 
Level of Evidence C
7.2 | Secondary cytoreduction
Secondary	cytoreduction	may	be	defined	as	an	attempt	at	cytoreduc-
tive	 surgery	 at	 some	 stage	 following	 completion	of	first-	line	 chemo-
therapy.	 Retrospective	 studies	 suggest	 that	 patients	 benefit	 if	 all	





debulking	 surgery	 has	 been	 addressed	 in	 the	DESKTOP	 III	 trial	 and	
the	results	recently	presented	by	Dubois	on	behalf	of	the	AGO.90 This 
study	included	patients	with	a	progression-	free	survival	of	greater	than	









will	only	be	available	in	a	few	years.	Level of Evidence C











1.	 Early	 recognition	 and	 prompt	 management	 of	 treatment-related	










are	 seen	every	3	months	with	a	gradual	 increase	 in	 intervals	 to	every	
4–6	months	 after	 2	years	 and	 then	 annually	 after	 the	 fifth	 year.	 At	
each	 follow-	up,	 the	patient	should	have	her	history	 retaken,	 including	
any	change	in	family	history	of	cancers	and	attention	to	any	symptoms	
that	could	suggest	recurrence;	a	physical	and	pelvic	examination	should	
be	performed.	This	 is	an	opportunity	 to	 refer	appropriate	patients	 for	
genetic	testing	if	it	was	not	done	at	diagnosis	or	during	treatment.	The	
CA125	 has	 traditionally	 been	 checked	 at	 regular	 intervals,	 but	 there	
has	been	debate	regarding	the	clinical	benefit	of	using	CA125	progres-
sion	alone	as	a	trigger	for	initiating	second-	line	chemotherapy.	A	large	









CT,	MRI,	 and/or	positron	emission	 tomography	 (PET)	 scans	should	be	
performed	only	when	the	clinical	findings	or	the	tumor	markers	suggest	
possible recurrence.
There	appears	 to	be	no	benefit	 to	 initiating	chemotherapy	 in	an	
























SOLO	283 19.1 5.5 0.3
NOVA84
gBRCA 21 5.5 0.27
Non-	BRCA 9.3 3.9 0.45
Non-	BRCA	HRD+ 12.9 3.8 0.38
ARIEL	3	85















in	 selected	 patients	with	 a	 rising	 CA125	 level,	 and	 the	 relationship	
between	estrogen	receptor	positivity	and	benefit	of	tamoxifen	in	this	
patient	population	is	being	evaluated	in	current	studies.
9  | CHEMOTHERAPY FOR RECURRENT 
EPITHELIAL MALIGNANCIES
The	majority	of	patients	who	present	with	advanced	epithelial	cancers	





prognosis	 has	 been	 the	 progression-	free	 interval	 or	 the	 “platinum-	
free	interval,”	which	is	defined	as	the	time	from	cessation	of	primary	





are	 classified	 as	 platinum	 resistant	 and	 generally	 treated	 with	
nonplatinum-	based	 chemotherapy,	 while	 those	 with	 a	 treatment-	




There	 have	 been	 modifications	 to	 these	 definitions,	 and	 time	
to	 progression	 or	 recurrence	 rather	 than	 treatment-	free	 interval	 or	
platinum-	free	 interval	has	been	used	to	define	specific	patient	pop-




progression	 alone	 at	 3	months	 post	 chemotherapy	 or	 radiological	







ICON	 4	 study	 showed	 advantage	 in	 terms	 of	 overall	 survival	 and	
progression-	free	survival	for	a	combination	of	carboplatin	and	pacli-
taxel	versus	single-	agent	carboplatin.96 Level of Evidence A
For	 patients	 with	 neurotoxicity,	 gemcitabine97 or liposomal 




with	 a	median	 progression-	free	 survival	 of	 11.3	 versus	 9.4	months,	
respectively.	There	was	no	significant	difference	in	the	overall	survival	
between	 the	 treatment	groups.	Median	overall	 survival	was	33	ver-
sus	30.7	months	for	the	CP	and	CD	arms,	respectively.	The	CD	arm	
was	better	tolerated	with	less	severe	toxicities,	and	this	combination	

















available	 clinical	 trials	or	 treatment	with	nonplatinum	chemotherapy	
should	be	considered.	There	are	a	number	of	chemotherapy	options	
including	liposomal	doxorubicin,101	topotecan,101	etoposide,102,103	and	




ovarian	 cancer,	 including	 epothilones,	 trabectedin106	 and	 perme-
trexed107	with	no	significant	increase	in	response	rates	or	progression-	
free	 survival.	 No	 new	 cytotoxic	 agent	 has	 been	 approved	 to	 treat	
recurrent	 ovarian	 cancer	 for	 many	 years.	 The	 role	 of	 angiogenesis	
inhibitors	in	platinum-	resistant	ovarian	cancer	is		discussed	below.
The	optimal	management	of	a	patient	with	platinum-	resistant	or	
refractory	 disease	 is	 complex	 and	 requires	 a	 careful	 assessment	 of	




aim	of	 treatment	 is	 to	maintain	quality	of	 life	and	palliate	symptoms	
particularly	in	patients	with	platinum-	resistant	ovarian	cancer.108 There 
are	many	potential	treatment	options,	including	chemotherapy,	angio-
genesis	 inhibitors,	 radiation	 therapy,	 or	 surgery	 in	 selected	 patients	
and	 inclusion	 in	 clinical	 trials.89	 There	 is	 a	 subset	 of	 patients	 who	
may	benefit	from	secondary	surgical	debulking,	but	they	constitute	a	
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minority.	The	role	of	secondary	surgical	debulking	is	being	addressed	in	
prospective	randomized	clinical	trials.	Level of Evidence C
9.1 | PARP inhibitors as monotherapy in patients 







with	 platinum-	resistant	 recurrent	 ovarian	 cancer	 and	 the	 median	
progression-	free	survival	was	7.9	months.110
Rucaparib	 is	 also	 approved	 for	 treatment	 of	 BRCA-	mutation-	
associated	advanced	ovarian	cancer	after	completion	of	treatment	with	
two	or	more	 chemotherapy	 regimens	 regardless	of	whether	patients	
are	platinum-	sensitive	or	resistant.111	Rucaparib’s	approval	was	based	
primarily	 on	 efficacy	 data	 from	 106	 patients	 with	 BRCA-	associated	





10  | MANAGEMENT OF EPITHELIAL 
TUMORS OF LOW- GRADE 
SEROUS CANCERS
Low-	grade	 serous	 cancers	 (LGSCs)	 comprise	 5%	 to	 10%	 of	 serous	



















LGSC.114	 A	 recent	 retrospective,	 exploratory,	 case-	control	 analysis	
of	 over	 5000	 patients	 receiving	 adjuvant	 chemotherapy	 in	 clinical	









10.1 | Management of low malignant potential 
(borderline) tumors
Compared	 with	 invasive	 epithelial	 cancers,	 borderline	 tumors	 tend	
to	 affect	 a	 younger	 population	 and	 constitute	 15%	 of	 all	 epithelial	
tumors	of	the	ovary.119	Nearly	75%	of	these	are	Stage	I	at	the	time	of	
diagnosis.	The	following	can	be	said	for	these	tumors120:













8.	 Those	 patients	 who	 have	 invasive	 implants	 in	 the	 omentum	 or	
other	distant	sites	are	more	likely	to	recur	earlier.	The	role	of	cyto-
toxic	chemotherapy	is	questionable	as	the	response	rates	are	low.
The	 causes	 of	 death	 include	 complications	 of	 disease	 (e.g.	 small	
bowel	obstruction)	or	complications	of	 therapy,	and	only	 rarely	malig-
nant	 transformation.	 The	 mainstay	 of	 treatment	 is	 primary	 surgical	
staging	and	cytoreduction.	For	patients	with	Stage	I	disease	who	want	







Patients	 with	 borderline	 tumors	 in	 all	 stages	 of	 disease	 should	
be	treated	with	surgery.	A	small	percentage	of	patients	with	invasive	











In	26	patients	with	 LGSC	of	 the	ovary	or	peritoneum,	 adjuvant	hor-


















by	 transvaginal	 ultrasonography,	 at	 least	 on	 an	 annual	 basis.1,120,126 
Level of Evidence C
11  | MANAGEMENT OF GRANULOSA 
CELL TUMORS
Granulosa	 cell	 tumors	 account	 for	 about	 70%	 of	 sex-	cord	 stromal	









and	histologic	 features.	 If	metastatic,	 adequate	cytoreduction	 is	 the	
mainstay	of	treatment.	If	the	patient	is	young	and	the	disease	is	con-
fined	to	one	ovary,	conservative	surgery	should	be	performed.128,129














pausal women. Level of Evidence C
12  | MANAGEMENT OF GERM 
CELL MALIGNANCIES
This	 group	 of	 ovarian	 tumors	 consists	 of	 a	 variety	 of	 histologically	
different	subtypes	that	are	all	derived	from	the	primitive	germ	cells	






















4.	 Teratoma	 (immature;	mature;	mature	with	 carcinoma	 [squamous	
cell,	carcinoid,	neuroectodermal,	malignant	struma,	etc.]).
5.	 Extraembryonal	 differentiation	 (choriocarcinoma;	 endodermal	
sinus	tumor	[yolk	sac	tumor]).
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intermediate,	and	poor	risk).	Dysgerminoma	is	the	equivalent	of	semi-
noma	 in	 testicular	 cancer.134	 It	 is	 exquisitely	 sensitive	 to	 platinum-	






As	 chemotherapy	 can	 cure	 the	 majority	 of	 patients,	 even	 with	
advanced	disease,	conservative	surgery	is	standard	in	all	stages	of	all	
germ	cell	tumors.	Conservative	surgery	means	laparotomy	with	careful	




















12.4 | Postoperative management and follow- up of 
dysgerminoma
Patients	with	Stage	IA	disease	may	be	observed	after	surgery.	A	small	
proportion	of	patients	may	 recur,	 but	 they	 can	be	 treated	 success-
fully	at	the	time	of	recurrence	with	a	high	rate	of	cure.	Patients	with	
disease	 beyond	 the	 ovary	 should	 receive	 adjuvant	 chemotherapy.	
Although	radiation	therapy	is	effective,	ovarian	failure	makes	it	unde-
sirable	for	patients	with	an	intact	ovary.
A	 follow-	up	 surveillance	 regime	 for	 patients	with	 Stage	1A	dys-
germinoma	is	outlined	in	Table	5.	This	schedule	is	based	on	the	expe-




Dysgerminoma	 is	 extremely	 sensitive	 to	 chemotherapy,	 and	 treat-
ment	with	 chemotherapy	 cures	 the	majority	 of	 patients,	 even	with	
advanced	disease.127,148	The	recommended	chemotherapy	regimen	is	
as	follows:








When	 there	 is	 bulky	 residual	 disease,	 it	 is	 common	 to	 give	 3–4	
courses	of	BEP	chemotherapy.148 Level of Evidence B
The	optimal	follow-	up	schedule	has	not	been	clinically	investigated	
in	ovarian	germ	cancers	and	the	frequency	of	visits	and	investigations	




can	be	 reduced,	which	 is	 similar	 to	 the	approach	 for	 testicular	germ	
cell	tumors.146	Each	follow-	up	visit	should	involve	taking	a	medical	his-
tory,	physical	examination,	and	tumor	marker	determination.	Although	
tumor	markers	 are	 important,	 radiological	 imaging	 is	 also	 pertinent,	



































first	2	years.	At	 relapse,	with	 few	exceptions,	 these	patients	 can	be	
successfully	treated.147 Level of Evidence D
12.5 | Postoperative management and follow- 
up of nondysgerminoma germ cell malignancies








m2	 per	 day	 for	 5	days	with	 cisplatin	 20	mg/m2	 per	 day	 for	 5	days,	






ifosfamide–cisplatin	 (TIP).137	 High-	dose	 chemotherapy	 and	 autolo-
gous	marrow	 rescue	may	 be	 considered	 in	 selected	 patients.	These	
patients	should	be	managed	in	specialized	units.
After	chemotherapy,	patients	with	metastatic	immature	teratomas	
can	 sometimes	 have	 residual	 masses,	which	 are	 composed	 entirely	
of	mature	elements.	These	masses	can	grow,	and	should	be	resected	
after	the	completion	of	chemotherapy.149 Level of Evidence B
All	 patients	 should	 have	 lactate	 dehydrogenase	 (LDH),	 alpha-	





Relapses	 in	 patients	 usually	 occur	 within	 the	 first	 2	years	 after	
diagnosis127,137 Level of Evidence D
13  | SARCOMA OF THE OVARY
Ovarian	 sarcomas	 are	 rare	 and	 occur	 primarily	 in	 postmenopausal	
patients.127,150	 Nevertheless,	 accurate	 diagnosis	 and	 differentiation	
from	other	types	of	primary	ovarian	cancer	are	important,	as	the	prog-
nosis is generally poor.
There	 are	 two	 types	 of	 sarcoma.	 Malignant	 mixed	 Müllerian	
tumors	(MMMTs),	the	more	common	of	the	two,	are	biphasic	tumors	






Pure	 sarcomas	are	very	 rare	and	should	be	 treated	according	 to	
the	specific	histologic	subtype.	These	rare	sarcomas	include	fibrosar-
comas,	 leiomyosarcomas,	 neurofibrosarcomas,	 rhabdomyosarcomas,	
chondrosarcomas,	 angiosarcomas,	 and	 liposarcomas.	 Their	 manage-
ment	is	not	discussed	here.





same	 as	 for	 high-	grade	 pelvic	 serous	 cancers.127	 Following	 surgery,	
patients	 should	 receive	platinum-	based	chemotherapy.127,147,148 The 
follow-	up	 schedule	 is	 as	 recommended	 for	 epithelial	 malignancies.	
Level of Evidence C
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